If you have risk factors for bone health problems—family history of osteoporosis, postmenopausal status, chronic kidney disease, or use of medications like corticosteroids—calcium testing provides baseline data. Testing is also relevant if you have symptoms suggestive of calcium dysregulation (muscle weakness, numbness around the mouth, palpitations) or are undergoing investigation for parathyroid disease or vitamin D deficiency.

That said, serum calcium is a poor marker of dietary calcium intake or bone health status. Many people with normal serum calcium have low bone mineral density, and conversely, some with low serum calcium have good bone structure. This is because PTH, calcitriol, and calcitonin work relentlessly to keep serum calcium within a narrow range (2.15–2.50 mmol/L), even when dietary intake or bone turnover changes significantly. A calcium test tells you whether parathyroid regulation is working, not whether your bones are strong or your diet is adequate.

Calcium testing is most useful in specific clinical contexts: screening for primary hyperparathyroidism, evaluating hypocalcaemia (low calcium) in the setting of vitamin D deficiency or chronic kidney disease, or monitoring calcium status in conditions affecting PTH, kidney, or vitamin D metabolism.

• Identifies parathyroid and mineral dysregulation. Abnormal serum calcium (high or low) often signals underlying PTH dysfunction, vitamin D deficiency, kidney disease, or other metabolic derangement that requires investigation.

• Detects primary and secondary hyperparathyroidism. Elevated calcium coupled with elevated PTH indicates primary hyperparathyroidism. Elevated calcium with suppressed PTH suggests alternative causes like malignancy, vitamin D toxicity, or granulomatous disease.

• Flags vitamin D deficiency consequences. Low calcium often clusters with vitamin D deficiency, especially in winter or with limited sun exposure, prompting vitamin D assessment and repletion.

• Monitors chronic kidney disease progression. Calcium dysregulation is a hallmark of advancing CKD as kidney function declines and PTH-mediated calcium reabsorption becomes impaired. Serial calcium monitoring guides phosphate binder and calcitriol supplementation decisions.

• Reveals medication-related effects. Certain diuretics (thiazides) raise calcium by increasing renal reabsorption; loop diuretics lower it. Calcium testing identifies these drug-induced shifts.

• Contextualizes bone markers with albumin. Corrected calcium accounts for serum albumin, ensuring that an apparent low calcium is not simply a reflection of hypoalbuminemia (malnutrition, liver disease, nephrotic syndrome), which would confound bone health assessment.

The mineral and its roles in the body. Calcium is the most abundant mineral in the human body, comprising ~2% of body weight. It serves multiple critical functions: structural support of bones and teeth (99% of body calcium resides here), electrical signalling in neurons and muscle cells, activation of coagulation cascades, regulation of enzyme activity, and control of hormone secretion. The remaining 1% circulates in blood and bathes every cell, where it must be maintained within an extraordinarily tight range (2.15–2.50 mmol/L in adults, or 1.15–1.30 mmol/L for ionized calcium) to prevent tetany, cardiac arrhythmia, or seizures.

Homeostatic control via PTH, calcitriol, and calcitonin. The body maintains serum calcium through a three-hormone feedback loop. When serum calcium drops even slightly, parathyroid glands sense this and secrete parathyroid hormone (PTH). PTH acts on kidney and bone to increase serum calcium through three mechanisms: (1) stimulating renal reabsorption of calcium in the collecting duct; (2) promoting renal conversion of calcidiol (25-OH vitamin D) to calcitriol (1,25-OH vitamin D), the active form that increases intestinal calcium absorption; and (3) promoting bone resorption by osteoclasts, releasing stored calcium into the bloodstream. Once calcium normalizes, PTH secretion shuts off. Conversely, if calcium rises above normal, the thyroid parafollicular cells release calcitonin, which inhibits osteoclasts and promotes renal calcium excretion. This exquisite feedback loop ensures calcium homeostasis is maintained independent of dietary intake—at least in the short term.

Total versus ionized calcium. The serum calcium measured in routine labs is total calcium, which includes protein-bound calcium (~40% bound to albumin, ~8% to globulins) and physiologically active ionized calcium (~52% free). Only ionized calcium is biologically available for cellular signalling and neuromuscular transmission. When albumin is low (from malnutrition, cirrhosis, or nephrotic syndrome), total calcium appears low even though ionized calcium and cellular function remain normal. This is why corrected calcium is calculated: Corrected Ca = Total Ca + (0.02 × [40 − Albumin]). Ionized calcium can be measured directly and is the gold standard in critical illness, but it is less commonly available in routine practice. For longevity and bone health assessment, understanding the albumin–calcium relationship is essential.

Calcium is not a marker of dietary intake. A critical and often misunderstood point: serum calcium does not reflect dietary calcium supply. A person eating virtually no calcium (extreme, but instructive) will have normal or even high serum calcium initially because PTH mobilizes calcium from bone to maintain homeostasis. Only over months to years, if dietary intake remains deficient and PTH cannot fully compensate, does serum calcium eventually fall. By contrast, someone with abundant dietary calcium and normal vitamin D status will not have higher serum calcium than someone eating less, because PTH simply lowers hormone levels to prevent hypercalcaemia. Serum calcium is a thermostat reading, not a measure of the furnace (diet) or the building insulation (bones). Assessing bone and dietary status requires DEXA scanning and dietary intake evaluation, not serum calcium alone.

• Identifies silent hyperparathyroidism and mineral loss risk. Primary hyperparathyroidism often causes no symptoms and is discovered only by finding elevated serum calcium or hypercalciuria (high urinary calcium loss). Untreated hyperparathyroidism accelerates bone loss, raises kidney stone risk, and impairs renal function. Testing calcium alongside PTH and vitamin D catches this condition before symptomatic complications emerge.

• Flags vitamin D deficiency and its consequences. Low serum calcium (especially when ionized calcium is measured) often signals vitamin D deficiency, a condition affecting 30–50% of Northern European populations in winter. Vitamin D deficiency causes secondary hyperparathyroidism, bone loss, muscle weakness, increased fracture risk, and is associated with higher all-cause mortality. Calcium and vitamin D testing together guide repletion strategies.

• Detects chronic kidney disease-mineral bone disease (CKD-MBD). As glomerular filtration rate declines, the kidneys lose ability to activate vitamin D and excrete phosphate, leading to secondary hyperparathyroidism, calcium dysregulation, and accelerated bone and cardiovascular calcification. Serum calcium, phosphate, and PTH are used together to monitor CKD-MBD and guide intervention before end-stage renal disease develops.

• Contextualizes cardiovascular risk from calcium dysregulation. Chronic hypercalcaemia increases risk of vascular and cardiac calcification, hypertension, and acute coronary events. Conversely, hypocalcaemia can cause QT prolongation and cardiac arrhythmias. While serum calcium alone is not a strong cardiovascular risk marker, it is part of the mineral-electrolyte landscape that influences vascular and cardiac function, especially when paired with phosphate, magnesium, and vitamin D status.

• Swedish clinical reference (adult, standard vårdcentral): 2.15–2.50 mmol/L (8.6–10.0 mg/dL). Values within this range are reported as normal by most laboratories and do not trigger clinical flags.

• Ionized (physiologically active) calcium reference: 1.15–1.30 mmol/L. This is the fraction available for cellular signalling. Ionized calcium may be measured when total calcium is borderline or when hypoalbuminemia or critical illness clouds interpretation.

• Loovi optimal (longevity baseline): 2.20–2.45 mmol/L (mid-to-upper half of normal range). This range reflects adequate calcium homeostasis without the extreme of hypercalcaemia. Paired with corrected calcium (accounting for albumin), vitamin D status (25-OH vitamin D >50 nmol/L), and PTH within normal range (1.6–7.0 pmol/L), this indicates stable mineral metabolism.

The clinically important thresholds are the extremes: values <2.10 mmol/L suggest hypocalcaemia (particularly if ionized calcium is measurably low), and values >2.65 mmol/L suggest hypercalcaemia. The step between normal and abnormal represents a shift in either PTH dysregulation, vitamin D status, or kidney function that warrants investigation. Most healthy adults cluster in the 2.25–2.45 mmol/L range without clinical consequence, but interpretation must always account for serum albumin, ionized calcium (if measured), and concurrent vitamin D and PTH status.

Low (<2.10 mmol/L or ionized <1.10 mmol/L). Hypocalcaemia (low serum calcium) indicates a breakdown in PTH-mediated or calcitriol-mediated calcium regulation. Common causes include vitamin D deficiency (insufficient sun exposure, dietary lack, malabsorption), hypoparathyroidism (PTH glands damaged by surgery, autoimmunity, or genetic cause), severe chronic kidney disease (kidneys cannot activate vitamin D or reabsorb calcium adequately), magnesium deficiency (magnesium is required for PTH secretion and action), or severe acute illness (sepsis, burn, transfusion reactions). Symptoms may be absent if hypocalcaemia is mild or gradual, but severe or acute hypocalcaemia causes perioral numbness, paresthesias, muscle cramps, tetany, and potentially seizures or cardiac arrhythmias. Hypocalcaemia requires investigation of PTH, vitamin D, magnesium, and kidney function to establish the cause.

Optimal (2.20–2.45 mmol/L with albumin 35–50 g/L and ionized 1.15–1.28 mmol/L). This range reflects stable mineral homeostasis. PTH is typically in the normal-to-low-normal range (1.6–4.0 pmol/L), vitamin D is adequate (>50 nmol/L 25-OH vitamin D), and kidney function is preserved. People in this range have favorable conditions for bone health and are not at immediate risk of calcium dysregulation complications. Longevity management focuses on maintaining this plateau through adequate vitamin D intake or sun exposure, adequate total dietary calcium (800–1200 mg daily depending on age and sex, from food sources ideally), and preservation of kidney function.

High (2.50–2.65 mmol/L). Mild hypercalcaemia warrants investigation. Causes include primary hyperparathyroidism (PTH glands overproduce PTH, driving calcium reabsorption), vitamin D toxicity (excess supplementation or granulomatous disease like sarcoidosis causing excessive calcitriol production), immobilization (prolonged bed rest or paralysis reduces bone resorption and shifts calcium balance), or thiazide diuretics (which increase renal calcium reabsorption). Investigation should include PTH level: if PTH is elevated or inappropriately normal with high calcium, primary hyperparathyroidism is likely. If PTH is suppressed (appropriately low), the source is vitamin D toxicity, malignancy, granulomatous disease, or medication-induced. Mild hypercalcaemia is often asymptomatic but can cause mild polyuria, polydipsia, or cognitive dullness over time.

Very High (>2.65 mmol/L). Significant hypercalcaemia requires urgent evaluation and intervention. Causes include advanced primary hyperparathyroidism, malignancy with PTHrP (parathyroid hormone-related peptide) secretion or osteolytic activity, vitamin D toxicity from excessive supplementation, or severe thyrotoxicosis. Symptoms may include nausea, vomiting, polyuria, dehydration, altered mental status, and cardiac arrhythmias. This level demands clinical assessment and may require IV saline, diuretics, or other acute interventions. Hospital evaluation is often needed.

Factors that influence calcium. Serum albumin is the primary confounder—a low serum albumin will lower total calcium without reflecting true ionized hypocalcaemia. Magnesium deficiency impairs PTH secretion and action, causing hypocalcaemia despite adequate vitamin D. Medications: thiazide diuretics raise calcium; loop diuretics and bisphosphonates can lower it. Vitamin D status (measured as 25-OH vitamin D) is perhaps the most influential long-term regulator of serum calcium; deficiency permits PTH to rise and causes secondary hypocalcaemia. Phosphate dysregulation (high phosphate suppresses calcitriol formation, lowering calcium) is particularly important in kidney disease. Pregnancy and lactation shift calcium metabolism to support fetal development and milk production, sometimes transiently altering serum calcium. Vitamin A toxicity (from supplement excess) can raise calcium by driving bone resorption. Acute illness, including sepsis, severe dehydration, or rhabdomyolysis, can acutely shift serum calcium.

• Vitamin D deficiency (hypocalcaemia). Inadequate sun exposure, dietary insufficiency, or malabsorption of vitamin D leads to low circulating 25-OH vitamin D. The kidneys cannot convert enough calcidiol to calcitriol, reducing intestinal calcium absorption. PTH rises in response, driving bone resorption to maintain serum calcium, but if vitamin D deficiency is severe enough or prolonged, serum calcium eventually falls. This is one of the most common causes of hypocalcaemia in Northern Europe, particularly in winter and in individuals with limited sun exposure or dark skin living at high latitude.

• Primary hyperparathyroidism (hypercalcaemia). The parathyroid glands overproduce PTH, usually due to a benign adenoma or nodular hyperplasia. This causes PTH to remain elevated even when serum calcium is high, driving the body into a state of inappropriate calcium excess. Calcium rises, PTH fails to suppress normally, and the condition is self-perpetuating. Primary hyperparathyroidism is more common in women, increases with age, and often remains asymptomatic for years before causing bone loss, kidney stones, or cognitive symptoms.

• Chronic kidney disease (hypocalcaemia and secondary hyperparathyroidism). As glomerular filtration rate declines, the kidneys lose the ability to activate vitamin D efficiently and cannot excrete excess phosphate. Serum calcium falls, PTH rises (secondary hyperparathyroidism), and the system enters a vicious cycle of bone loss, vascular calcification, and mineral dysregulation. This becomes progressively worse as kidney function declines toward end-stage renal disease.

• Malignancy (hypercalcaemia). Certain cancers—particularly squamous cell lung cancer, breast cancer, renal cell carcinoma, and ovarian cancer—secrete PTHrP (parathyroid hormone-related peptide) or produce calcitriol, driving hypercalcaemia independent of normal PTH control. This is a medical emergency and signals advanced, often metastatic disease. Hypercalcaemia from malignancy is typically severe (>3.0 mmol/L) and accompanied by symptoms.

• Medications and immobilization (hypercalcaemia). Thiazide diuretics increase renal calcium reabsorption and can cause modest hypercalcaemia. Vitamin D supplementation in excess raises calcium. Prolonged immobilization (paraplegia, severe bed rest) allows unchecked bone resorption without the mechanical stimulus to build bone, raising calcium. Vitamin A toxicity from supplement excess drives bone resorption.

• Hypoparathyroidism (hypocalcaemia). Genetic defects, autoimmune destruction, or surgical removal of the parathyroid glands eliminate PTH secretion, causing hypocalcaemia that cannot be corrected by vitamin D alone. Ionized calcium is characteristically low with elevated serum phosphate. This is a rare but serious cause of symptomatic hypocalcaemia.

• Magnesium deficiency (hypocalcaemia). Magnesium is required for PTH secretion and for PTH's action on target tissues. Severe hypomagnesaemia (often from chronic diarrhea, diuretics, or PPI use) prevents adequate PTH response to hypocalcaemia. Paradoxically, magnesium deficiency can appear alongside hypercalciuria and kidney stones, creating a complex picture that resolves only when magnesium is repleted.

Vitamin D sufficiency is foundational. Maintaining serum 25-OH vitamin D at >50 nmol/L (and optimally 75–100 nmol/L for longevity) is the primary lever for stable calcium homeostasis. Adequate sun exposure (10–30 min midday sun, several times per week, depending on latitude and skin tone) or supplementation (typically 1000–2000 IU daily, higher in winter or with limited sun exposure) ensures efficient intestinal calcium absorption and suppresses excess PTH secretion. Without adequate vitamin D, no amount of dietary calcium will normalize calcium and PTH fully.

Adequate dietary calcium from food sources. The recommended dietary allowance for calcium is 800–1200 mg daily depending on age and sex. Whole food sources (fermented dairy like yogurt and cheese, leafy greens like kale, canned fish with bones, legumes, nuts) are preferable to supplements because they provide calcium alongside other minerals (magnesium, phosphate, potassium, trace metals) and nutrients that support mineral metabolism holistically. Calcium supplements, when needed, should be taken with food and in divided doses (no more than 500 mg per dose) for optimal absorption.

Magnesium sufficiency. Magnesium is required for PTH secretion and action. Maintaining magnesium status (serum 0.75–1.05 mmol/L, or ionized 0.5–0.6 mmol/L) is essential for calcium regulation. Magnesium sources include nuts, seeds, dark leafy greens, legumes, whole grains, and dark chocolate. In cases of chronic diarrhea or high-dose diuretic use, magnesium supplementation may be needed.

Bone health beyond calcium: strength training and mechanical loading. Bone density and strength depend not only on mineral supply but on mechanical stimulus. Resistance training (weight-bearing exercise, strength work) stimulates osteoblasts to build bone, independent of serum calcium levels. Regular physical activity (including balance and coordination work to prevent falls) is one of the strongest long-term predictors of fracture risk in older age. Sedentary people with normal serum calcium have worse bone outcomes than active people with lower-normal calcium.

Preserve kidney function. Kidney function is the linchpin of long-term calcium homeostasis. Protecting glomerular filtration rate by managing blood pressure (target <130/80 mmHg), avoiding nephrotoxic exposures, controlling blood glucose (HbA1c <5.3%), and limiting protein intake to moderate levels (1.0–1.2 g/kg body weight) all preserve the kidney's ability to reabsorb calcium and activate vitamin D. Chronic kidney disease is the most common driver of calcium dysregulation in aging populations.

Monitor and interpret in context. Serum calcium should be interpreted alongside albumin (to calculate corrected calcium), vitamin D status (25-OH vitamin D), PTH, and magnesium. In the setting of preserved kidney function and adequate vitamin D, most people maintain optimal serum calcium through diet and lifestyle. In the context of kidney disease, hyperparathyroidism, or severe vitamin D deficiency, medication-based interventions (calcitriol, phosphate binders, calcimimetics) may be required. The right approach depends on the full biomarker picture and the underlying cause of any dysregulation—exactly the kind of synthesis that a Loovi longevity doctor evaluates in consultation.

Serum calcium alone tells an incomplete story. A normal calcium result does not rule out vitamin D deficiency, magnesium depletion, or early kidney disease. Conversely, a low or high calcium result requires investigation of PTH, vitamin D, phosphate, magnesium, kidney function (creatinine and eGFR), and albumin to determine the underlying cause and appropriate intervention. Testing calcium without this context can lead to unnecessary supplementation (if you assume low calcium means you need more dietary calcium, ignoring that the problem is vitamin D deficiency or kidney disease) or missed diagnosis (if you reassure someone with normal calcium that their bones are fine, missing that they have primary hyperparathyroidism causing silent bone loss).

The Loovi Membership measures 120+ biomarkers annually, including comprehensive mineral metabolism (calcium, phosphate, magnesium, vitamin D, PTH, albumin), kidney function (creatinine, eGFR, cystatin C), and related markers like bone turnover and endocrine function. Paired with unrushed 1-on-1 longevity doctor consultations, DEXA bone density scanning (where indicated), and an evolving personalized health plan, Loovi ensures that calcium dysregulation is contextualized within the full picture of mineral, endocrine, and kidney health. From 295 SEK/month, Friskvårdsbidrag-approved, with drop-in testing at 80+ Swedish clinics and results in 3 days.